News and Announcements
BPS Technology (ASX: BPS) Ltd Appoints New CEO
- Published November 24, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- BPS Technology has appointed Mr Iaian Dunstan as CEO commencing December 4, 2017.
- Mr Dunstan has vast experience of 30 years in the technology and finance industry.
- Information of Mr Dunstan’s remuneration package will soon be disclosed to the market.
BPS Technology Ltd has made a change to the leadership of the company as newly appointed Mr Iain Dunstan joining as the company’s Chief Executive Officer (CEO) starting on December 4, 2017.
Mr Dunstan will be responsible for driving BPS Technology to the next level, continuing the solid momentum and foundation achieved by BPS Technology under Mr Trevor Dietz’ leadership. Mr Dunstan has vast experience of 30 years in the technology and finance industry with encompassing broad company milieu.
In May 2017, Mr Dunstan as the CEO of the ASX-listed Rubik Financial Limited leads the sale of the company to the Terminos Group. Previously he was the Founder and CEO of Bravura Solutions Limited, an ASX listed company that has an annual turnover of not less than $125 million, which he built and expanded into nine countries all over the world staffed with over 700 talented, diverse professionals. The Ernst & Young Entrepreneur of the Year Award in the Technology, Communications, e-Commerce and Life Sciences Category was awarded to Mr Dunstan last 2007.
Heidrick & Struggles, an executive search firm, eyed on Mr Dunstan as the perfect, highly qualified candidate for the duty of becoming the BPS’ latest CEO. At the General Meeting of all the BPS shareholders held on November 3rd, 2017, Mr Dunstan was initially offered as a BPS Director and as CEO by two past shareholders and was repudiated by shareholders.
Upon recognition and thorough judgment of the Independent Directors of Mr Dunstan’s vast experience, they opposed his election at the aforesaid General Meeting subjected to conducting a shareholder nominate the next CEO in the lack of any selection, or due diligence process was deemed inadmissible. Subsequently, as propounded by the Independent Directors, Mr Dunstan presented his CV to Heidrick & Struggles, who had facilitated the search following the confirmation of Mr Dietz’ imminent resignation from the post. Joining the list of top-profiled candidates, Mr Dunstan was interviewed by the recruitment firm.
Mr. Murray d’Almeida, Chairman of BPS and his co-directors are very delighted that Mr. Dunstan has accepted the Board’s invitation to continue Mr. Dietz’ tasks, as he stated: “As founding CEO, Trevor will leave big shoes to fill and we thank him for the leadership, hard work and commitment he has shown to help build BPS into a leading provider of transactional platforms and management systems, with a reach of 3.5 million consumers. He leaves the position of CEO with the business well positioned for further growth that delivers superior returns for all our shareholders. We are grateful that Trevor has agreed to assist in the transition process. I know that Iain will benefit from his deep knowledge of our Company and of the many personal and business relationships that are so important to us”, Mr d’Almeida said.
About BPS Technology Ltd
BPS Technology Limited (ASX: BPS) provides technology and payment platforms centred on SME’s.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
